Skyscraper: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab with or without Tiragolumab (Anti-Tigit Antibody) in Patients with Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma